{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T08:24:33Z","timestamp":1766305473276,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002573","name":"Yonsei University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.xphs.2019.03.022","type":"journal-article","created":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T02:57:32Z","timestamp":1553914652000},"page":"2765-2773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimal Dosing Regimen of Phenytoin for Korean Epilepsy Patients: From Premature Babies to the Elderly"],"prefix":"10.1016","volume":"108","author":[{"given":"Jinju","family":"Guk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Guk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwoo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyungsoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2019.03.022_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01720610-201202000-00002","article-title":"Phenytoin: an old friend that still confuses us","volume":"25","author":"Bamberg","year":"2012","journal-title":"JAAPA"},{"issue":"6","key":"10.1016\/j.xphs.2019.03.022_bib2","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1006\/ebeh.2001.0283","article-title":"The expert consensus guideline series: treatment of epilepsy","volume":"2","author":"Karceski","year":"2001","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.xphs.2019.03.022_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2005.06.001","article-title":"Treatment of epilepsy in adults: expert opinion, 2005","volume":"7","author":"Karceski","year":"2005","journal-title":"Epilepsy Behav"},{"issue":"7240","key":"10.1016\/j.xphs.2019.03.022_bib4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/bmj.320.7240.953","article-title":"Managing status epilepticus - new drug offers real advantages","volume":"320","author":"Heafield","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.xphs.2019.03.022_bib5","first-page":"1","article-title":"Clinical decision making in seizures and status epilepticus","volume":"17","author":"Teran","year":"2015","journal-title":"Emerg Med Pract"},{"issue":"2","key":"10.1016\/j.xphs.2019.03.022_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"10.1016\/j.xphs.2019.03.022_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF01059685","article-title":"The clinical pharmacokinetics of phenytoin","volume":"5","author":"Martin","year":"1977","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"issue":"4","key":"10.1016\/j.xphs.2019.03.022_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198308040-00006","article-title":"Steady-state pharmacokinetics of phenytoin from routinely collected patient data","volume":"8","author":"Grasela","year":"1983","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther"},{"year":"2013","series-title":"Variability in Human Drug Response","author":"Smith","key":"10.1016\/j.xphs.2019.03.022_bib10"},{"issue":"5","key":"10.1016\/j.xphs.2019.03.022_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0009-9236(98)90100-X","article-title":"What are narrow therapeutic index drugs?","volume":"63","author":"Levy","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.xphs.2019.03.022_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0387-7604(94)90108-2","article-title":"Role of therapeutic drug monitoring (TDM) in pediatric anti-convulsant drug dosing","volume":"16","author":"Walson","year":"1994","journal-title":"Brain Dev"},{"issue":"2","key":"10.1016\/j.xphs.2019.03.022_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/003693308503000202","article-title":"Therapeutic drug monitoring\u2014the need for audit?","volume":"30","author":"Brodie","year":"1985","journal-title":"Scott Med J"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/201010581302200307","article-title":"Phenytoin: a guide to therapeutic drug monitoring","volume":"22","author":"Wu","year":"2013","journal-title":"Proc Singapore Healthc"},{"issue":"1","key":"10.1016\/j.xphs.2019.03.022_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/FTD.0b013e3182763739","article-title":"Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug","volume":"35","author":"Lee","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00007691-198905000-00011","article-title":"Clinical utility of a Bayesian dosing program for phenytoin","volume":"11","author":"Privitera","year":"1989","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.xphs.2019.03.022_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF01068078","article-title":"Predicting individual phenytoin dosage","volume":"9","author":"Vozeh","year":"1981","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2019.03.022_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2710.1990.tb00352.x","article-title":"Phenytoin dosage individualization\u2013five methods compared in the elderly","volume":"15","author":"Hudson","year":"1990","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.xphs.2019.03.022_bib19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/clpt.1988.211","article-title":"Phenytoin pharmacokinetics in critically ill trauma patients","volume":"44","author":"Boucher","year":"1988","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.xphs.2019.03.022_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.arcmed.2004.11.006","article-title":"Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients","volume":"36","author":"Aarons","year":"2005","journal-title":"Arch Med Res"},{"issue":"22","key":"10.1016\/j.xphs.2019.03.022_bib21","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1001\/archinte.159.22.2639","article-title":"Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process","volume":"159","author":"Meek","year":"1999","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.xphs.2019.03.022_bib22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jama.1983.03330300046032","article-title":"Complications of intravenous phenytoin for acute treatment of seizures: recommendations for usage","volume":"249","author":"Earnest","year":"1983","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.xphs.2019.03.022_bib23","first-page":"137","article-title":"Guidelines for phenytoin infusions","volume":"37","author":"Tuttle","year":"1984","journal-title":"Can J Hosp Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2019.03.022_bib24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF01060053","article-title":"Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data","volume":"8","author":"Sheiner","year":"1980","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2019.03.022_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","article-title":"Factors and mechanisms for pharmacokinetic differences between pediatric population and adults","volume":"3","author":"Fernandez","year":"2011","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00002512-199915030-00006","article-title":"Differential kinetics of phenytoin in elderly patients","volume":"15","author":"Bachmann","year":"1999","journal-title":"Drugs Aging"},{"issue":"9","key":"10.1016\/j.xphs.2019.03.022_bib27","first-page":"708","article-title":"Phenytoin dosing in obese patients: two case reports","volume":"22","author":"de Oca","year":"1988","journal-title":"Drug Intell Clin Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.tpj.6500025","article-title":"The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels","volume":"1","author":"Kerb","year":"2001","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1016\/j.xphs.2019.03.022_bib30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/gtmb.2011.0225","article-title":"Role of MDR1 C3435T and GABRG2 C588T gene polymorphisms in seizure occurrence and MDR1 effect on anti-epileptic drug (phenytoin) absorption","volume":"16","author":"Ponnala","year":"2012","journal-title":"Genet Test Mol Biomarkers"},{"issue":"7","key":"10.1016\/j.xphs.2019.03.022_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5414\/CP203083","article-title":"The association between CYP2C9\/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: a systematic review and meta-analysis","volume":"56","author":"Liao","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.xphs.2019.03.022_bib32","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1021\/js9702168","article-title":"Influence of race or ethnicity on pharmacokinetics of drugs","volume":"86","author":"Johnson","year":"1997","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/03602539508998331","article-title":"Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors","volume":"27","author":"Edeki","year":"1995","journal-title":"Drug Metab Rev"},{"issue":"4","key":"10.1016\/j.xphs.2019.03.022_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00008571-200106000-00002","article-title":"The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement","volume":"11","author":"van der Weide","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"9","key":"10.1016\/j.xphs.2019.03.022_bib35","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A\u00a0pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2019.03.022_bib36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.xphs.2019.03.022_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2125.2000.00231.x","article-title":"A\u00a0model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children","volume":"50","author":"Anderson","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2019.03.022_bib38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"year":"2010","series-title":"Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice","author":"Yaffe","key":"10.1016\/j.xphs.2019.03.022_bib39"},{"issue":"12","key":"10.1016\/j.xphs.2019.03.022_bib40","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/j.1651-2227.1996.tb13942.x","article-title":"Pharmacokinetics and renal function in preterm infants","volume":"85","author":"van den Anker","year":"1996","journal-title":"Acta Paediatr"},{"issue":"1","key":"10.1016\/j.xphs.2019.03.022_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2125.1975.tb00475.x","article-title":"Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding","volume":"2","author":"Hayes","year":"1975","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib42","first-page":"489","article-title":"Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers","volume":"69","author":"Tanaka","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2019.03.022_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1212\/01.wnl.0000316392.55784.57","article-title":"Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy","volume":"71","author":"Ahn","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.xphs.2019.03.022_bib44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/clpt.2009.192","article-title":"Pediatric drug development: concepts and applications","volume":"86","author":"MacLeod","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.xphs.2019.03.022_bib45","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/adc.52.4.302","article-title":"Pharmacokinetic observations of phenytoin disposition in the newborn and young infant","volume":"52","author":"Loughnan","year":"1977","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1208\/s12248-009-9131-2","article-title":"Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates","volume":"11","author":"Pai","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2019.03.022_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eplepsyres.2005.07.017","article-title":"Pharmacological and clinical aspects of antiepileptic drug use in the elderly","volume":"68","author":"Perucca","year":"2006","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.xphs.2019.03.022_bib48","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archneur.1985.04060050066010","article-title":"Phenytoin disposition in obesity. Determination of loading dose","volume":"42","author":"Abernethy","year":"1985","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.xphs.2019.03.022_bib49","first-page":"448","article-title":"Contributions of CYP2C9\/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting","volume":"40","author":"Lee","year":"2007","journal-title":"J\u00a0Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.xphs.2019.03.022_bib50","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00007691-200410000-00012","article-title":"Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9\/CYP2C19 polymorphisms","volume":"26","author":"Hung","year":"2004","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919301716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919301716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:26:21Z","timestamp":1758360381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354919301716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0022354919301716"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2019.03.022","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal Dosing Regimen of Phenytoin for Korean Epilepsy Patients: From Premature Babies to the Elderly","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2019.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}